Search

Search Constraints

You searched for: Author/Creator Larrey, Dominique

Search Results

11. Cover Image. Issue 10 (21st April 2021)

12. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. (8th March 2017)

13. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Issue 12 (21st September 2010)

14. Diagnosis and management of hepatic encephalopathy: The French recommendations. (24th January 2023)

15. Direct, indirect and total effect of HIV coinfection on the risk of non‐liver‐related cancer in hepatitis C virus‐infected patients treated by direct‐acting antivirals: a mediation analysis. Issue 10 (17th August 2021)

16. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. (1st September 2018)

17. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. (22nd March 2020)

18. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Issue 4 (10th July 2018)

19. Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results. Issue 8 (November 2013)

20. Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial12. Issue 6 (12th June 2013)